Sign Out
There are no adequate and well-controlled studies on the use of XELJANZ in pregnant women. Tofacitinib has been shown to be teratogenic in rats and rabbits, and have effects in rats on female fertility, parturition, and peri/post-natal development (see Pharmacology: Toxicology: Non-clinical safety data under Actions). XELJANZ should not be used during pregnancy unless clearly necessary.
Women of reproductive potential should be advised to use effective contraception during treatment with XELJANZ and for at least 4 weeks after the last dose.
Tofacitinib was secreted in the milk of lactating rats (see Pharmacology: Toxicology: Non-clinical safety data under Actions). It is not known whether tofacitinib is secreted in human milk. Women should not breastfeed while treated with XELJANZ.
